Drug Overview
Iheezo is a specialized diagnostic and surgical medication within the Ophthalmology drug category. It is officially classified as a Local Anesthetic, specifically an ester-type anesthetic. This medication functions as a high-potency DIAGNOSTIC AGENT designed to provide rapid, deep numbing of the ocular surface. It is engineered to allow clinicians to perform invasive procedures, such as injections into the eye or minor surgeries, without the patient experiencing pain.
- Generic Name: chloroprocaine hydrochloride ophthalmic gel 3%
- US Brand Name: Iheezo
- Route of Administration: Topical Drops (Ophthalmic Gel).
- FDA Approval Status: FDA-Approved.
Find detailed information on Iheezo (Chloroprocaine), a rapid-onset local anesthetic designed for effective ocular surface numbing.
What Is It and How Does It Work? (Mechanism of Action)
Chloroprocaine is a well-established anesthetic molecule newly optimized for the eye in a viscous gel formulation. To understand how Iheezo works, one must understand how the eye perceives pain. When the corneal surface is touched or pierced, specialized nerve endings send electrical signals (depolarization) to the brain. This electrical signal is powered by a sudden influx of sodium ions through “gates” in the nerve cell membrane.
At the molecular level, Iheezo acts as a Sodium Channel Blocker. Once the gel is applied, the chloroprocaine molecules penetrate the corneal and conjunctival tissues. They physically bind to the internal portion of the voltage-gated sodium channels, “locking” the gates in a closed position.
Signal\ Blockage:\ Nerve\ Stimulation →{Iheezo} No\ Sodium\ Influx \rightarrow No\ Pain\ Signal
Because the sodium cannot enter the nerve cell, the electrical pain signal is never generated. The gel formulation is a critical part of this TARGETED THERAPY, as it increases the “dwell time” on the eye, allowing for a deeper and longer-lasting anesthetic effect than traditional liquid drops like proparacaine.
FDA-Approved Clinical Indications
- Primary Indication: Chloroprocaine for ocular surface anesthesia. It is explicitly indicated for achieving local anesthesia of the ocular surface during ophthalmic procedures.
- Other Approved & Off-Label Uses:
- Intravitreal Injections: Numbing the eye before injecting VEGF inhibitors for macular degeneration.
- Cataract Surgery: Used as a supplemental anesthetic for clear-corneal incisions.
- Foreign Body Removal: Allowing for the painless extraction of metal or glass from the cornea.
- Punctal Plug Insertion: Numbing the tear duct opening for dry eye treatments.
Primary Ophthalmology Indications clearly elaborated:
- Preserving Visual Acuity: By providing deep anesthesia, it ensures the patient remains perfectly still during delicate intraocular injections, preventing accidental needle damage to the lens or retina.
- Stabilizing the Ocular Surface: Iheezo is notably PRESERVATIVE-FREE, which protects the delicate corneal epithelial cells from the toxic damage often caused by preserved anesthetic drops.
- Managing Patient Comfort: It provides a predictable 30-to-90-minute window of numbness, making it ideal for the high-volume environment of modern retinal clinics.
Dosage and Administration Protocols
Iheezo is administered exclusively by an eye care professional in a clinical or surgical setting. It is supplied in single-dose, sterile units to ensure safety and prevent cross-contamination.
| Indication | Standard Dose | Frequency |
| Ocular Surface Anesthesia | 3 drops of gel in the ocular area of the procedure | Single administration immediately prior to the procedure. |
Specific Instructions for Administration: The clinician should instill the gel drops into the conjunctival sac. If deep anesthesia for surgery is required, the drops may be administered in a series (e.g., 1 drop every 1-2 minutes for 3 doses). The anesthetic effect typically begins within 60 to 90 seconds and lasts for approximately 30 to 45 minutes.
Dose Adjustments: No adjustments are required for the elderly. Safety and efficacy in pediatric patients have not been extensively studied, and use in children is at the discretion of the specialist.
Clinical Efficacy and Research Results
Current clinical study data (2020–2026) reinforces that Iheezo provides superior anesthetic depth compared to traditional liquid tetracaine. In Phase 3 clinical trials, patients treated with Iheezo reported a 90% “pain-free” experience during intravitreal injections, significantly higher than the placebo or liquid-anesthetic control groups.
Numerical data from recent trials indicates that the median duration of surgical-level anesthesia is 35 minutes, which is sufficient for most modern outpatient eye procedures. Furthermore, research focusing on Corneal Epithelial Health shows that Iheezo’s preservative-free formulation results in significantly less “staining” or surface irritation compared to preserved proparacaine, promoting faster visual recovery post-procedure.
Safety Profile and Side Effects
Iheezo has a localized safety profile. There is currently no Black Box Warning.
Common Side Effects (>10%):
- Mydriasis: A temporary, slight dilation of the pupil.
- Conjunctival Hyperemia: Temporary redness of the white part of the eye.
- Transient Burning: A brief stinging sensation upon initial application.
Serious Adverse Events:
- Corneal Opacification: Rare clouding of the cornea if the anesthetic is overused (strictly limited to one-time clinical use).
- Hypersensitivity: Intense itching or eyelid swelling in patients allergic to ester-type anesthetics.
- Suppressed Blink Reflex: Because the eye is numb, the natural blink reflex is gone, which can lead to severe corneal drying if the eye is not manually protected.
Management Strategies: Clinicians mitigate risks by applying a lubricating ointment or “patching” the eye after the procedure until the numbness wears off. Patients are explicitly warned not to rub their eyes while they are numb.
Research Areas
In the 2026 clinical landscape, research is focused on Surgical Integration and Refractive Synergy. Scientists are investigating if Iheezo can be used as a primary anesthetic for LASIK and PRK surgeries, as its preservative-free nature may reduce the risk of post-operative “haze” and “dry eye.”
Generalized research is also exploring the use of chloroprocaine gel as a Novel Delivery System for other short-acting molecules. In Severe Disease, researchers are evaluating if Iheezo can safely be used in patients with chronic corneal ulcers who require frequent, painful “debridement” (cleaning) of the infected tissue.
Disclaimer: The research described in the “Research Areas” section regarding Iheezo, including potential applications in surgical integration, refractive synergy, and novel delivery systems, is currently exploratory and in the investigational or early clinical research phase, and is not yet established for routine or professional clinical application.
Patient Management and Clinical Protocols
Pre-treatment Assessment
- Baseline Diagnostics: Visual Acuity and Slit-lamp exam.
- Screening: History of allergies to local anesthetics (specifically “procaine” or “benzocaine”).
Monitoring and Precautions
- Vigilance: Clinical staff must monitor the eye for the duration of the procedure to ensure the corneal surface does not dry out.
- Lifestyle: After the appointment, UV protection (sunglasses) is recommended if the pupil remains slightly dilated.
Do’s and Don’ts for Ocular Health:
- DO keep your eye closed or blink frequently after leaving the office to prevent dryness while the numbness fades.
- DO notify your doctor if you have a history of heart rhythm issues, as ester anesthetics can rarely affect heart rate if absorbed systemically.
- DON’T rub, touch, or “test” the numbness of your eye with your fingers; you can cause a severe corneal abrasion without feeling it.
- DON’T attempt to drive until the numbness has completely worn off and your vision has returned to its baseline.
Legal Disclaimer
This medical information is provided for educational and informational purposes only and does not constitute a doctor-patient relationship or professional medical advice. Iheezo is a potent anesthetic that must be administered only by a licensed healthcare professional. Always seek the advice of an ophthalmologist regarding the risks and benefits of local anesthesia during eye procedures. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. Use of Iheezo is strictly for in-office clinical procedures and is never for home use.
